| Title |
Glioblastoma antigen discovery—foundations for immunotherapy
|
|---|---|
| Published in |
Journal of Neuro-Oncology, June 2015
|
| DOI | 10.1007/s11060-015-1836-8 |
| Pubmed ID | |
| Authors |
Tej D. Azad, Seyed-Mostafa Razavi, Benjamin Jin, Karen Lee, Gordon Li |
| Abstract |
Prognosis for patients with glioblastoma (GBM), the most common high-grade primary central nervous system (CNS) tumor, remains discouraging despite multiple discoveries and clinical advances. Immunotherapy has emerged as a promising approach to GBM therapy as the idea the human CNS is immunoprivileged is being challenged. Early clinical studies of vaccine-based approaches have been encouraging, but further investigation is required before these therapies become clinically meaningful. A key challenge in immunotherapy involves identification of target antigens that are specific and sensitive for GBM. Here we discuss tumor-associated antigens that have been targeted for GBM therapy, strategies for discovery of novel antigens, and the theory of epitope spreading as it applies to GBM immunotherapy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 3% |
| Brazil | 1 | 3% |
| Unknown | 35 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 24% |
| Student > Ph. D. Student | 7 | 19% |
| Other | 3 | 8% |
| Student > Doctoral Student | 3 | 8% |
| Student > Bachelor | 3 | 8% |
| Other | 5 | 14% |
| Unknown | 7 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 27% |
| Agricultural and Biological Sciences | 8 | 22% |
| Biochemistry, Genetics and Molecular Biology | 3 | 8% |
| Neuroscience | 3 | 8% |
| Social Sciences | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 9 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2015.
All research outputs
#18,345,259
of 23,577,654 outputs
Outputs from Journal of Neuro-Oncology
#2,202
of 3,039 outputs
Outputs of similar age
#181,962
of 268,255 outputs
Outputs of similar age from Journal of Neuro-Oncology
#25
of 65 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,039 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,255 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.